A 45-year-old woman with a 2-month history of epigastric pain, early satiety, and nausea undergoes upper endoscopy, which shows antral gastritis with intestinal metaplasia. Rapid urease test on antral biopsy is positive. Serology for anti-H. pylori IgG is also positive. What is the most appropriate next step in management?

Explanation

## Helicobacter pylori Infection: Diagnosis and Treatment Initiation ### Diagnostic Confirmation **Key Point:** This patient has *multiple concordant positive tests* confirming active *H. pylori* infection: - **Rapid urease test (RUT):** Positive on antral biopsy — indicates urease-producing bacteria *in situ* - **Serology (anti-H. pylori IgG):** Positive — confirms prior or current exposure - **Endoscopic findings:** Antral gastritis with intestinal metaplasia — consistent with *H. pylori*-associated chronic inflammation **High-Yield:** RUT positivity is the gold standard for confirming *active* infection at the time of endoscopy. Serology alone cannot distinguish past from current infection, but in combination with RUT and clinical symptoms, it confirms diagnosis. ### First-Line Treatment: Triple Therapy **Mnemonic:** **OAC** = Omeprazole, Amoxicillin, Clarithromycin (14 days) | Component | Role | Dose | |-----------|------|------| | **Omeprazole** | PPI; raises gastric pH to optimize antibiotic efficacy | 20 mg BD | | **Amoxicillin** | β-lactam; excellent gastric penetration | 1 g BD | | **Clarithromycin** | Macrolide; intracellular penetration | 500 mg BD | | **Duration** | Standard course | 14 days | **Clinical Pearl:** Triple therapy achieves eradication rates of 85–95% in regions with low clarithromycin resistance (< 15%). In India, resistance varies by region but triple therapy remains first-line for treatment-naïve patients. ### Why NOT Delay with Further Testing? **Warning:** Stool antigen testing and culture/susceptibility are NOT required before initiating therapy in a treatment-naïve patient with confirmed diagnosis. Delaying treatment: - Prolongs symptoms and risk of complications (ulcer, MALT lymphoma) - Increases bacterial burden and transmission - Is not supported by any guideline ### Post-Treatment Verification **Key Point:** Test-of-cure (urea breath test, stool antigen, or serology) is performed 4–6 weeks *after* completing therapy to confirm eradication, not before initiation.